Affiliation:
1. Immuno-Oncology Program, Ares Pharmaceuticals, St. Paul, MN 55110, USA
Abstract
We examined the transcript-level expression of ErbB family protein tyrosine kinases, including ERBB1, in primary malignant lymphoma cells from 498 adult patients with diffuse large B-cell lymphoma (DLBCL). ERBB1 expression in DLBCL cells was significantly higher than in normal B-lineage lymphoid cells. An upregulated expression of ERBB1 mRNA in DLBCL cells was correlated with an amplified expression of mRNAs for transcription factors that recognized ERBB1 gene promoter sites. Notably, amplified ERBB1 expression in DLBCL and its subtypes were associated with significantly worse overall survival (OS). Our results encourage the further evaluation of the prognostic significance of high-level ERBB1 mRNA expression and the clinical potential of ERBB1-targeting therapeutics as personalized medicines in high-risk DLBCL.
Reference58 articles.
1. EGF receptor;Wells;Int. J. Biochem. Cell Biol.,1999
2. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors;Sabbah;Curr. Top. Med. Chem.,2020
3. ErbB Receptors and Cancer;Wang;Methods Mol. Biol.,2017
4. Bhanumathy, K.K., Balagopal, A., Vizeacoumar, F.S., Vizeacoumar, F.J., Freywald, A., and Giambra, V. (2021). Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia. Cancers, 13.
5. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles;Santos;Int. J. Pharm.,2021